VRTX

Vertex Pharmaceuticals
D

VRTX

484.53
USD
4.10
(0.85%)
مغلق
حجم التداول
59,797
الربح لكل سهم
17
العائد الربحي
-
P/E
-233
حجم السوق
124,422,395,227
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 6 أشهر
    buy
    VRTX
    VRTX
    2024-08-22 10:31
    VRTX Chart
    المزيد
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    E
    EXEL
    1.750
    (4.99%)
    36.830 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    I
    IONS
    -0.365
    (-1.12%)
    32.310 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    المزيد
الأخبار
المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.